



PRESS RELEASE

ASLAN PHARMACEUTICALS TO PRESENT AT THE ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE 2022

Menlo Park, California, and Singapore, April 6, 2022, – ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present at the 21st Annual Needham Virtual Healthcare Conference. The conference will be held virtually from April 11 to 14, 2022.

Presentation details

Date: Thursday, April 14, 2022

Time: 10:15 - 10:55am ET

Format: Company presentation

Track: 2

Click [here](#) to listen-in live or via replay. This link will also be posted in the News & Events section of ASLAN Pharmaceutical's Investor Relations website at <https://ir.aslanpharma.com/>.

Ends

Media and IR contacts

Emma Thompson

Spurwing Communications

Tel: +65 6206 7350

Email: ASLAN@spurwingcomms.com

Ashley R. Robinson

LifeSci Advisors, LLC

Tel: +1 (617) 430-7577

Email: arr@lifesciadvisors.com

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating *eblasakimab*, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and *farudodstat* (also known as ASLAN003), a potent oral inhibitor of the enzyme, DHODH, in autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on [LinkedIn](#).